AMD Publications

The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration

Retina

January 2022

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis

Translational vision science & technology

November 2021

Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence

Eye

October 2021

Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands

Acta Ophthalmologica

September 2021

Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry

Clinical & Experimental Ophthalmology

September 2021

Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater

Clinical and Experimental Ophthalmology

August 2021

Association between anatomical and clinical outcomes of neovascular age-related macular degeneration treated with anti-VEGF

Retina

July 2021

Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry

Graefe’s Archive for Clinical and Experimental Ophthalmology

June 2021

Five-year incidence and visual acuity outcomes for intravitreal therapy in bilateral neovascular age-related macular degeneration: Fight Retinal Blindness! Project

Retina

January 2021

Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration

JAMA Ophthalmology

December 2020

Prevalence and risk factors for the development of physician-graded subretinal fibrosis in eyes treated for neovascular age-related macular degeneration

Retina

December 2020

Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration

Clinical and Experimental Ophthalmology

September 2020

Email: ssi.ssr@sydney.edu.au
Phone: (+61) 421 787 808

Level 1, South Block
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000

AMD Publications

The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis

Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence

Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands

Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry

Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater

Association between anatomical and clinical outcomes of neovascular age-related macular degeneration treated with anti-VEGF

Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry

Five-year incidence and visual acuity outcomes for intravitreal therapy in bilateral neovascular age-related macular degeneration: Fight Retinal Blindness! Project

Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration

Prevalence and risk factors for the development of physician-graded subretinal fibrosis in eyes treated for neovascular age-related macular degeneration

Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration

Follow us

Quick links